Impulsivity and AMPA receptors: Aniracetam ameliorates impulsive behavior induced by a blockade of AMPA receptors in rats

Brain Research

Volumn 862, Issue 1-2, 2000, Pages 266-269

  Nakamura, Kazuo ^a   Kurasawa, Mitsue ^a   Shirane, Masatoshi ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

AMPA; AMPA receptor antagonist; Aniracetam; Choice reaction task; Impulsivity; Premature response

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; ANIRACETAM;

ANIMAL EXPERIMENT; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; IMPULSIVENESS; MALE; NERVE PROJECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SHORT SURVEY; TASK PERFORMANCE;

EID: 0034678703     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02160-0     Document Type: Article

References (25)

1. Baumgarten H.G., Grozdanovic Z. Psychopharmacology of central serotonergic systems. Pharmacopsychiatry. 28:(Suppl. 2):1995;73-79.
2. Chapman A.G., Al-Zubaidy Z., Meldrum B.S. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice. Eur. J. Pharmacol. 231:1993;301-303.
3. 3H]dopamine release from nucleus accumbens slices and monoamine levels in a rat model for attention deficit hyperactivity disorder. Neurochem. Res. 20:1995;427-433.
4. Gottfries C.G., Blennow K., Karlsson I., Wallin A. The neurochemistry of vascular dementia. Dementia. 5:1994;163-167.
5. Harrison A.A., Everitt B.J., Robbins T.W. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology. 133:1997;329-342.
6. Harrison A.A., Everitt B.J., Robbins T.W. Doubly dissociable effects of median- and dorsal-raphé lesions on the performance of the five-choice serial reaction time test of attention in rats. Behav. Brain Res. 89:1997;135-149.
7. Himori N., Mishima K. Amelioration by aniracetam of abnormalities as revealed in choice reaction performance and shuttle behavior. Pharmacol. Biochem. Behav. 47:1994;214-225.
8. Katsunuma H., Shimizu T., Ogawa K., Kubo H., Ishida H., Yoshihama A. Treatment of insomnia by concomitant therapy with zopiclone and aniracetam in patients with cerebral infarction, cerebroatrophy. Alzheimer's disease and Parkinson's disease. Psychiatry Clin. Neurosci. 52:1994;198-200.
9. Lu Y., Wehner J.M. Enhancement of contextual fear-conditioning by putative (±)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice. Brain Res. 768:1997;197-207.
10. Maione S., Rossi F., Biggs C.S., Fowler L.J., Whitton P.S. AMPA receptors modulate extracellular 5-hydroxytryptamine concentration and metabolism in rat striatum in vivo. Neurochem. Int. 30:1997;299-304.
11. Maione S., Palazzo E., de Novellis V., Stella L., Leyva J., Rossi F. Metabotropic glutamate receptors modulate serotonin release in the rat periaqueductal gray matter. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;411-417.
12. Martin J.R., Haefely W.E. Pharmacology of aniracetam: A novel pyrrolidinone derivative with cognition enhancing activity. Drug Invest. 5:(Suppl. 1):1993;4-49.
13. Nakamura K., Kurasawa M., Tanaka Y. Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. Drug Dev. Res. 43:1998;85-97.
14. Nakamura K., Kurasawa M., Tanaka Y. Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam. Eur. J. Pharmacol. 342:1998;127-138.
15. Nakamura K., Shirane M. Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam. Eur. J. Pharmacol. 380:1999;81-89.
16. Nicoletti F., Casabona G., Genazzani A.A., Copani A., Aleppo G., Canonico P.L., Scapagnini U. Excitatory amino acids and neuronal plasticity: modulation of AMPA receptors as a novel substrate for the action of nootropic drugs. Func. Neurol. 7:1992;413-422.
17. Otomo E., Hirai S., Terashi A., Hasegawa K., Tazaki Y., Araki G., Ito E., Nishimura T., Furukawa T. Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: Double-blind trial in placebo. J. Clin. Exp. Med. 156:1991;143-187.
18. Pizzi M., Fallacara C., Arrighi V., Memo M., Spano P. Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. J. Neurochem. 61:1993;683-689.
19. Scearce-Levie K., Chen J.P., Gardner E., Hen R. 5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders. Ann. NY Acad. Sci. 868:1999;701-715.
20. Singewald N., Kaehler S.T., Hemeida R., Philippu A. Influence of excitatory amino acids on basal and sensory stimuli-induced release of 5-HT in the locus coeruleus. Br. J. Pharmacol. 123:1998;746-752.
21. Stein D.J., Hollander E., Liebowitz M.R. Neurobiology of impulsivity and the impulse control disorders. J. Neuropsychiatry Clin. Neurosci. 5:1993;9-17.
22. Tao R., Ma Z., Auerbach S.B. Influence of AMPA/kainate receptors on extracellular 5-hydroxytryptamine in rat midbrain raphe and forebrain. Br. J. Pharmacol. 121:1997;1707-1715.
23. Tuinier S., Verhoeven W.M., van Praag H.M. Cerebrospinal fluid 5-hydroxyindolacetic acid and aggression: a critical reappraisal of the clinical data. Int. Clin. Psychopharmacol. 10:1995;147-156.
24. Whitton P.S., Maione S., Biggs C.S., Fowler L.J. Tonic desensitization of hippocampal alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors regulates 5-hydroxytryptamine release in vivo. Neuroscience. 63:1994;945-948.
25. Wogar M.A., Bradshaw C.M., Szabadi E. Effects of lesions of the ascending 5-hydroxytryptamine pathways on choice between delayed reinforcers. Psychopharmacology. 111:1993;239-243.